VHPB Centre for Evaluation of Vaccination (CEV) |
Executive Secretary Administrative and Scientific Secretariat |
privacy statement
|
Meeting objectives:
Background document (PDF, 912 kB)
Thursday 28 October 2021
Part I - HEPATITIS D CURRENT CONTEXT
Introduction Part I
Chairs: VHPB secretariat
16:00 - 16h:20 Welcome and opening of the meeting
• Welcome and opening
• Introduction of the participants
Greet Hendrickx
Session 1.1: Introduction Hepatitis Delta
Chairs: Karine Lacombe and Erika Duffell
16:20 - 16:35 The changing context of hepatitis Delta – 45 years after the discovery of Hepatitis D virus: where do we stand?
Francesco Negro
Session 1.2: Epidemiology and Burden of Disease of Hepatitis Delta
Chairs: Karine Lacombe and Erika Duffel
16:35 - 17:40 The Global prevalence and Burden of Disease of Hepatitis D
Alexander Stockdale
Country examples
France:
Dominique Roulot
Germany:
Sandra Dudareva
Georgia:
Mamuka Zakalashvili
Session 1.3: Occurence of Hepatitis Delta
Chairs: Daniel Shouval and Vladimir Chulanov
17:40 - 17:55 May Hepatitis D occur in Hepatitis B negative patients?
Natalia Freitas
Session 1.4: Diagnostics, screening and taxonomy of Hepatitis Delta
Chairs: Daniel Shouval and Vladimir Chulanov
17:55 - 18:25 Overview of current diagnostics for hepatitis Delta
Emmanuel Gordien
Genotyping: diagnostic tools and new classification of hepatitis Delta genotyping
Hadi Karimzadeh
18:25 - 18:50 Discussion: Needs for Screening of hepatitis D
18:50 - 19:00 Conclusions of the day
Friday 29 October 2021
Part II - HEPATITIS DELTA PREVENTION AND CONTROL
Introduction Part II
VHPB secretariat
16:00 - 16:15 Short resume Day 1
Rapporteur
Session 2.1: Prevention
Chairs: Pierre Van Damme
16:15 - 16:30 Does the use of Hepatitis B vaccine prevent Hepatitis Delta?
Cesar Cabezas
Session 2.2: Treatment and control
Chairs: Thomas Vanwolleghem and John Ward
16:30 - 16:45 Overview of treatment options (including novel treatment)
Pietro Lampertico
16:45 - 17:00 Longterm hepatitis D treatment success
Cihan Yurdaydin
17:00 - 17:45 Expert Panel Debate
Since a lot of researchers are working on Hepatitis D treatment current and future.
Each panel member will be asked to record their opinion on Hep D treatment based on 3 question. A summary will be shared during the meeting and afterwards, an interactive discussion will be held with all participants.
Panel: Pietro Lampertico/ Stephan Urban/ Victor Deledinghen/ Cihan Yurdaydin/ Andrew Vaillant
Session 2.3: Groups discussion: Should elimination of hepatitis D be included in WHO Elimination goals
Chairs: Paige Armstrong And Antons Mozolevskis
17:45 - 18:00 Do we need to consider Hepatitis D as a public health problem?
Bob Gish
18:00 - 18:45 Final groups discussion
Should elimination of hepatitis D be included in WHO elimination goals.
18:45 - 19:00 Conclusion and closing of the meeting
Meeting report by David FitzSimons (PDF, 1.669 kB)